Evotec SE header image

Evotec SE

EVT

Equity

ISIN DE0005664809 / Valor 505433

Xetra (2026-07-28)

EUR 3.50+2.34%

Evotec SE
UMushroom community rating:

4.29 7 votes No rating yet

NegativeNeutralPositive

About company

Evotec SE is a global drug discovery and development partnership company headquartered in Germany, specializing in providing integrated solutions to the pharmaceutical and biotechnology industries. The company leverages its extensive expertise in areas such as medicinal chemistry, biology, and data science to support the development of new therapeutics across various therapeutic areas, including neuroscience, oncology, and metabolic diseases. Evotec collaborates with a diverse range of partners, including major pharmaceutical companies, biotech firms, and academic institutions, to advance innovative drug candidates from early discovery through clinical development. In the first quarter of 2025, Evotec reported progress in strategic partnerships and the implementation of initiatives aimed at achieving sustainable and profitable growth, reinforcing its position as a key player in the biopharmaceutical landscape.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-52.9%1Y

-84.8%3Y

-90.0%5Y

Performance

54.6%1Y

67.5%3Y

60.1%5Y

Volatility

708 M

Market cap (USD)

707,352

Daily traded volume (Shares)

8.73 / 8.45

1 day high/low (USD)

0.00 / 0.00

52 weeks high/low (USD)

01 January, 2022

Dividend ex-date

0.00

Dividend (USD)

0.00%

Dividend yield (p.a.)

0.002022

0.002023

0.002024

Est dividend (USD)

0.00%2022

0.00%2023

0.00%2024

Est dividend yield

10.00

P/E ratio

00.002022

00.002023

00.002024

Est P/E ratio

0.00

EPS (USD)

0.002022

0.002023

0.002024

Est EPS (USD)

Ratings & reviews

4.29

7 votes

Performance:

4.29

Innovation:

4.29

Society:

4.00

Nature:

3.86

Meret Jaggi

Switzerland, 30 May 2022

Oliver Moon

Switzerland, 30 May 2022

German biotech/ pharma company. Decent upside potential. Analyst buy. Good performance history. Seems good to me.

Atanas WI Atanasov

Switzerland, 30 May 2022

EQUITIES OF THE SAME SECTOR

Orion Oyj

Orion Oyj Valor: 2553367

Annual Return

-50%0%+50%

Risk level

110

1.51%EUR 80.75

Orion Oyj

Orion Oyj Valor: 2553360

Annual Return

-50%0%+50%

Risk level

110

1.64%EUR 80.50

Siemens Healthineers AG

Siemens Healthineers AG Valor: 40652181

Annual Return

-50%0%+50%

Risk level

110

1.01%EUR 35.92

Merck KGaA

Merck KGaA Valor: 412799

Annual Return

-50%0%+50%

Risk level

110

1.76%EUR 144.25

Fresenius SE & Co. KGaA

Fresenius SE & Co. KGaA Valor: 332902

Annual Return

-50%0%+50%

Risk level

110

0.11%EUR 44.30

Carl Zeiss Meditec AG

Carl Zeiss Meditec AG Valor: 1055489

Annual Return

-50%0%+50%

Risk level

110

2.57%EUR 28.74

Haemonetics Corp

Haemonetics Corp Valor: 937449

Annual Return

-50%0%+50%

Risk level

110

3.29%USD 82.54

Dermapharm Holding SE

Dermapharm Holding SE Valor: 40166352

Annual Return

-50%0%+50%

Risk level

110

2.45%EUR 41.75

Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals Inc Valor: 30877188

Annual Return

-50%0%+50%

Risk level

110

-1.18%USD 55.30

Formycon AG

Formycon AG Valor: 12194189

Annual Return

-50%0%+50%

Risk level

110

0.43%EUR 18.90

SIX

FactSet

Clearbit

Logos provided by Clearbit